NASDAQ:PMVP PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis $1.67 +0.24 (+16.78%) Closing price 09/30/2026 04:00 PM EasternExtended Trading$1.66 -0.01 (-0.60%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About PMV Pharmaceuticals Stock (NASDAQ:PMVP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PMV Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.44▼$1.7350-Day Range$1.07▼$1.6752-Week Range$1.02▼$1.88Volume3.12 million shsAverage Volume596,578 shsMarket Capitalization$89.28 millionP/E RatioN/ADividend YieldN/APrice Target$4.33Consensus RatingModerate Buy Company Overview PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company focused on developing therapies that target cancer-driving genetic mutations. The company uses its proprietary research platform to discover and develop small-molecule medicines designed to restore the activity of mutated tumor-suppressor proteins. PMV’s lead product candidate is rezatapopt (PC14586), an oral small-molecule therapy designed to reactivate the p53 protein when it carries the Y220C mutation. The candidate is being evaluated in patients with advanced solid tumors harboring this specific mutation, including through the company’s PYNNACLE clinical trial. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals focuses on oncology drug discovery and clinical development. Its programs are directed toward genetically defined cancers, with development activities primarily conducted in the United States and through clinical research networks.AI Generated. May Contain Errors. Read More PMV Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScorePMVP MarketRank™: PMV Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 162nd out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingPMV Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPMV Pharmaceuticals has a consensus price target of $4.33, representing about 159.5% upside from its current price of $1.67.Amount of Analyst CoveragePMV Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about PMV Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PMV Pharmaceuticals are expected to grow in the coming year, from ($1.26) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PMV Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PMV Pharmaceuticals is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPMV Pharmaceuticals has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about PMV Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.08% of the float of PMV Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPMV Pharmaceuticals has a short interest ratio ("days to cover") of 2.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PMV Pharmaceuticals has recently increased by 28.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPMV Pharmaceuticals does not currently pay a dividend.Dividend GrowthPMV Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.95 News SentimentPMV Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for PMV Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for PMVP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added PMV Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PMV Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.15% of the stock of PMV Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.20% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PMV Pharmaceuticals' insider trading history. Receive PMVP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMVP Stock News HeadlinesPMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Rated "Moderate Buy" by Sell-Side BrokeragesSeptember 29 at 6:14 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), PMV Pharmaceuticals (PMVP) and Tyra Bioscience (TYRA)September 9, 2026 | theglobeandmail.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)PMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt FilingSeptember 9, 2026 | rttnews.comPMV Pharmaceuticals Appoints Philip Herman as Chief Commercial OfficerSeptember 8, 2026 | finance.yahoo.comPMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal TrialSeptember 1, 2026 | finanznachrichten.dePMV Pharma Posts Interim Phase 2 PYNNACLE Ovarian Cancer Data; Prices $50.8 Mln Offering; Stock DownSeptember 1, 2026 | rttnews.comPMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences OfferingSeptember 1, 2026 | finance.yahoo.comSee More Headlines PMVP Stock Analysis - Frequently Asked Questions How have PMVP shares performed this year? PMV Pharmaceuticals' stock was trading at $1.25 at the beginning of 2026. Since then, PMVP stock has increased by 33.6% and is now trading at $1.67. How were PMV Pharmaceuticals' earnings last quarter? PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) released its earnings results on Friday, August, 14th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.05. When did PMV Pharmaceuticals IPO? PMV Pharmaceuticals (PMVP) raised $200 million in an IPO on Friday, September 25th 2020. The company issued 11,765,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO. How do I buy shares of PMV Pharmaceuticals? Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PMV Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that PMV Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), NIO (NIO), Meta Platforms (META), Plug Power (PLUG), Aptose Biosciences (APTO), Clean Energy Fuels (CLNE) and Intel (INTC). Company Calendar Last Earnings8/14/2026Today9/30/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, PMVP's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PMVP CIK1699382 Webwww.pmvpharma.com Phone609-642-6670FaxN/AEmployees54Year Founded2013Price Target and Rating Average Price Target for PMV Pharmaceuticals$4.33 High Price Target$5.00 Low Price Target$3.00 Potential Upside/Downside+159.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$77.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-78.11% Return on Assets-70.13% Debt Debt-to-Equity RatioN/A Current Ratio7.70 Quick Ratio7.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.97 per share Price / Book0.85Miscellaneous Outstanding Shares53,460,000Free Float48,032,000Market Cap$89.28 million OptionableOptionable Beta1.37 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PMVP) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
